Literature DB >> 20958231

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.

Sham Mailankody1, Esther Mena, Constance M Yuan, Arun Balakumaran, W Michael Kuehl, Ola Landgren.   

Abstract

Multiple myeloma (MM) is a malignant plasma cell dyscrasia localized in the bone marrow. Recent studies have shown that MM is preceded in virtually all cases by a premalignant state called monoclonal gammopathy of undetermined significance (MGUS). This review focuses on non-IgM MGUS and its progression to MM. Although certain clinical markers of MGUS progression have been identified, it currently is not possible to accurately determine individual risk of progression. This review focuses on the various biologic and molecular markers that could be used to determine the risk of MM progression. A better understanding of the pathogenesis will allow us to define the biological high-risk precursor disease and, ultimately, to develop early intervention strategies designed to delay and prevent full-blown MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20958231      PMCID: PMC7032041          DOI: 10.3109/10428194.2010.525725

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  63 in total

1.  Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.

Authors:  Fenghuang Zhan; Erming Tian; Klaus Bumm; Ruston Smith; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

Review 2.  Monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

3.  A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly.

Authors:  M Bowden; J Crawford; H J Cohen; O Noyama
Journal:  J Am Geriatr Soc       Date:  1993-01       Impact factor: 5.562

4.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

5.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 6.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

7.  Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.

Authors:  Nicole Véronique Smadja; Dominique Leroux; Jean Soulier; Sylvie Dumont; Catherine Arnould; Sylvie Taviaux; Jean Louis Taillemite; Christian Bastard
Journal:  Genes Chromosomes Cancer       Date:  2003-11       Impact factor: 5.006

8.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.

Authors:  N V Smadja; C Fruchart; F Isnard; C Louvet; J L Dutel; N Cheron; M J Grange; M Monconduit; C Bastard
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

9.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.

Authors:  Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Shimera Kamihira; Masao Tomonaga
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

10.  DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.

Authors:  Timothy J Ley; Elaine R Mardis; Li Ding; Bob Fulton; Michael D McLellan; Ken Chen; David Dooling; Brian H Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E Larson; Dan C Koboldt; Craig Pohl; Scott Smith; Amy Hawkins; Scott Abbott; Devin Locke; Ladeana W Hillier; Tracie Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua Conyers; Nathan Sander; Xiaoqi Shi; John R Osborne; Patrick Minx; David Gordon; Asif Chinwalla; Yu Zhao; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark Watson; Jack Baty; Jennifer Ivanovich; Sharon Heath; William D Shannon; Rakesh Nagarajan; Matthew J Walter; Daniel C Link; Timothy A Graubert; John F DiPersio; Richard K Wilson
Journal:  Nature       Date:  2008-11-06       Impact factor: 49.962

View more
  11 in total

Review 1.  Early lymphoid lesions: conceptual, diagnostic and clinical challenges.

Authors:  Karthik A Ganapathi; Stefania Pittaluga; Oreofe O Odejide; Arnold S Freedman; Elaine S Jaffe
Journal:  Haematologica       Date:  2014-09       Impact factor: 9.941

Review 2.  Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Authors:  Sham Mailankody; Neha Korde; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

Review 3.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Authors:  Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

Review 4.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

5.  Proteomic profiling in plasma cell disorders: a feasibility study.

Authors:  Sham Mailankody; Sean M Devlin; Neha Korde; Nikoletta Lendvai; Alexander Lesokhin; Heather Landau; Hani Hassoun; Andrea Ballagi; Daniel Ekman; David J Chung; Minal Patel; Guenther Koehne; Sergio Giralt; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2016-12-02

6.  Multiple myeloma precursor disease.

Authors:  Ola Landgren; Adam Justin Waxman
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

7.  When an Analytical Interference Is a Useful Diagnostic Tool: Finding Monoclonal Gammopathies in Routine Analysis.

Authors:  Carmen Quiñones-Torrelo; María Pilar Villanueva-Gil; Ana Rodríguez-Muñoz; Lidia Abellán-Tejada; Manuel Aparici-Ibáñez; Arturo Carratalá-Calvo
Journal:  J Clin Lab Anal       Date:  2014-12-26       Impact factor: 2.352

8.  The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.

Authors:  Bénedith Oben; Charlotte Cosemans; Ellen Geerdens; Loes Linsen; Kimberly Vanhees; Brigitte Maes; Koen Theunissen; Bert Cruys; Marta Lionetti; Ingrid Arijs; Niccolò Bolli; Guy Froyen; Jean-Luc Rummens
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

9.  Indolent cytotoxic T cell lymphoproliferation associated with nodular regenerative hyperplasia: a common liver lesion in the context of common variable immunodeficiency disorder.

Authors:  Vanessa Szablewski; Céline René; Valérie Costes
Journal:  Virchows Arch       Date:  2015-10-22       Impact factor: 4.064

10.  Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.

Authors:  Alexander Zheleznyak; Matthew Mixdorf; Lynne Marsala; Julie Prior; Xiaoxia Yang; Grace Cui; Baogang Xu; Steven Fletcher; Francesca Fontana; Gregory Lanza; Samuel Achilefu
Journal:  Theranostics       Date:  2021-06-22       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.